Peptides in skin care are short amino acid chains added to creams to signal fibroblasts, the cells that build collagen, and the evidence behind them is thinner than the marketing implies. The cleanest human result belongs to pal-KTTKS (Matrixyl) at 3 parts per million, which cut wrinkles and fine lines over 12 weeks in a double-blind split-face trial of 93 Caucasian women, run by the manufacturer's own scientists and never independently replicated. GHK-Cu, the copper peptide most people buy, has no randomized facial trial in a PubMed-indexed journal with a positive blinded outcome: its famous 67-woman result was a manufacturer-funded conference abstract that never became a paper. The one independent facial trial, 13 patients after CO2 laser resurfacing, found no difference on computer analysis or blinded graders while only the patients' own questionnaires favored it. Topical retinoids and daily sunscreen still hold the trial record; a peptide is the experiment layered on top.
Peptides commonly discussed for skin aging
Safety: Nothing here is medical advice, a dosing protocol or an acquisition guide. Injectable GHK-Cu, epitalon, BPC-157, TB-500 and KPV are not FDA approved for human use. All five were placed in Category 2 of the FDA's interim 503A bulk substances list in September 2023 and were removed on 22-23 April 2026 when the nominators withdrew their nominations; FDA's stated safety concerns about them are still published on the same page. Removal is not authorization: none has been added to Category 1, so licensed compounding pharmacies still may not legally prepare them, and no FDA-approved sterile injectable GHK-Cu product exists in the US for facial use. Facial injection carries infection, granuloma (a hard lump of inflamed scar-like tissue) and vascular injury risks that a cream does not, and vascular injury in the face can cause tissue death or vision loss; self-injecting the face is unsafe in every scenario. Anyone with Wilson's disease should avoid GHK-Cu in any form. Hold peptide use in pregnancy and breastfeeding, and note that prescription retinoids are contraindicated in pregnancy. Regulatory status here is stated as of August 2026 and this file is moving. Bring any of this to a board-certified dermatologist before acting on it.
Where to buy
Where to get peptides for skin aging
GHK-Cu
Compare providers →Epithalon
Buy at Swiss Chems →Save 10% at checkout with code tcwisiiu
Some links are affiliate links — we may earn a fee at no extra cost to you. Most peptides aren't FDA-approved — consult a qualified clinician and check your local laws before purchasing.
The copper peptide GHK-Cu dominates the peptide skin care market on a mechanism literature going back to 1988 and, on our search of PubMed to August 2026, no randomized facial trial in an indexed journal with a positive blinded result. The peptide with the cleanest human evidence, pal-KTTKS, has a 93-woman split-face trial behind it 5 and almost no marketing. Both are peptides: short strings of amino acids, the building blocks of protein, put into creams to signal skin cells to build more collagen.
What peptides in skin care are, and what they do to skin
A peptide is a short chain of amino acids, shorter than a protein. The ones in skin care are called signal peptides because the claim is that they act as messages rather than as ingredients: a fragment that resembles a piece of broken collagen tells a fibroblast, the cell that builds the skin's scaffolding, that there is damage to repair. GHK-Cu carries an extra piece, a copper ion held in a stable grip, and copper is required by lysyl oxidase, the enzyme that cross-links collagen and elastin into springy tissue 3. The problem all of this is aimed at is measurable: type I collagen in human skin falls by roughly one percent a year after age 25 7.
Two different products share the word peptide, and the confusion is what sells copper serums. A cosmetic peptide goes onto the skin at parts-per-million concentrations inside a cream, and a few of them have small split-face trials behind them. A research peptide goes under the skin as an injection, comes as a freeze-dried powder from a supplier that labels it not for human use, and has no facial-aging outcome data. GHK-Cu is sold in both forms, from the same three-letter name, on the strength of the same laboratory papers.
How a copper peptide is supposed to work on a face
How the skin peptides grade against retinoids and sunscreen
The column that decides everything here is what each study measured, and in whom. Below is the whole field for facial aging, peptides and non-peptides together, sorted by the strength of the human evidence rather than by how hard each is sold.
| Option | Best human evidence | Who and how long | What was measured | US status |
|---|---|---|---|---|
| Topical tretinoin (a retinoid) | Randomized, double-blind, compared against the identical cream with the drug left out 6 | 30 adults completed, 16 weeks; 14 of 15 tretinoin-treated faces improved, none of the drug-free-cream faces did | Photoaging graded clinically, plus histology on forearm skin | FDA-approved prescription drug; adapalene 0.1% sells over the counter |
| Daily broad-spectrum sunscreen | Regulated and reviewed as a drug, not as a cosmetic | Standard daily use | Sun protection factor by standardized testing | FDA over-the-counter drug monograph |
| Topical pal-KTTKS (Matrixyl), 3 ppm | Double-blind, placebo-controlled, split-face randomized study 5 | 93 Caucasian women aged 35 to 55, 12 weeks; one manufacturer-run trial, never independently replicated | Wrinkles and fine lines by image analysis and by expert graders | Cosmetic ingredient, no efficacy review; study run by the manufacturer's own scientists |
| Topical GHK-Cu | One independent randomized facial trial 1 | 13 patients completed, assessed 12 weeks after CO2 laser resurfacing; this tests wound aftercare, not intact aging skin | Erythema by computer analysis was the primary endpoint; wrinkles and skin quality by blinded evaluators: no significant difference on any of them | Cosmetic ingredient, no efficacy review |
| Injectable GHK-Cu | None found as of August 2026 | No trial has been published | Nothing | Not FDA approved; left 503A Category 2 in April 2026 without entering Category 1, so still not compoundable |
| Epitalon (epithalon) | Human data is for epithalamine, the pineal extract it was modeled on 4 | Elderly patients with coronary disease followed 12 years; the abstract does not report how many | Functional age, exercise tolerance, mortality: no skin endpoint at any point | Not FDA approved; left 503A Category 2 in April 2026 without entering Category 1, so still not compoundable |
| BPC-157 | None for skin aging | No trial has been published on aging skin | Nothing on wrinkles, firmness or pigment | Not FDA approved; left 503A Category 2 in April 2026 without entering Category 1, so still not compoundable |
The cosmetic peptide at the top of that table is the one almost nobody asks about. Pal-KTTKS, sold as Matrixyl, was tested at 3 parts per million inside an ordinary moisturizer against the same moisturizer without it, on opposite halves of 93 faces for 12 weeks, and it reduced wrinkles and fine lines on both instrument image analysis and expert grading 5. Procter & Gamble employed the authors. It is still a randomized split-face design with objective grading, which is more than the copper peptide has. On an ingredient list it appears as palmitoyl pentapeptide-4, usually branded Matrixyl, and it turns up in ordinary drugstore moisturizers, so trying the peptide with the trial behind it does not require a $90 serum. Verdict on the best-evidenced peptide on this page: one 12-week trial in Caucasian women aged 35 to 55, run by the manufacturer's own scientists and never replicated by anyone else, is a reason to try pal-KTTKS rather than a reason to believe it, and it is still a weaker bet than the retinoid you can buy for $15.
The nearest thing to an exception deserves naming, because it is cited inside this page's own reference 3. Badenhorst and colleagues (J Aging Sci 2016;4:166) ran a randomized double-blind 8-week facial trial in 40 women aged 40 to 65 and reported a 55.8 percent reduction in wrinkle volume against a control serum. Three things keep it out of the table above: J Aging Sci is an OMICS title that is not indexed in MEDLINE, so it does not appear in a PubMed search; it tested GHK-Cu carried in a nano-lipid formulation rather than a conventional serum, which is not what a shopper buys; and nobody has replicated it. It exists, and it does not carry the weight of the trials graded above.
Can GHK-Cu be absorbed through the skin?
Partly, and it depends on the formulation more than on the peptide. GHK is a three-amino-acid peptide of about 340 daltons, small enough that skin penetration is chemically plausible, and the copper complex, at roughly 402 daltons, changes both its size and its charge 3. What no published study establishes is how much of an applied dose reaches living skin from any particular serum on a particular face, which is why absorption arguments in product copy are chemistry rather than measurement.
The practical consequence runs one way: a serum result cannot be transferred to an injection, and an injection result cannot be transferred to a serum. They deliver different amounts to different depths. When a vendor cites cell-culture collagen work to sell an injectable, the argument has skipped both.
Where a serum label falls% GHK-Cu in a cream
The most-quoted GHK-Cu face result never became a paper
Almost every page selling copper peptide for wrinkles traces back to one source: Leyden and colleagues, Skin Care Benefits of Copper Peptide Containing Facial Cream, presented at the American Academy of Dermatology 60th Annual Meeting in New Orleans, 22 to 27 February 2002, with manufacturer support. It reported improvements in firmness, fine lines and pigmentation over 12 weeks. Two details are worth holding. It was never published as a peer-reviewed journal paper; searching PubMed for Leyden with copper peptide, to August 2026, returns no indexed record of it. And secondary sources disagree on the size of it, with retellings variously giving 67 and 71 women, which is what happens when the primary source is a poster. Conference abstracts are not peer-reviewed and carry no methods section a reader can check.
A conference abstract is a claim with a poster attached. A paper is a claim other people were allowed to attack first.
The one independent facial trial of GHK-Cu was negative on the objective measures
Miller and colleagues randomized patients who had undergone CO2 laser resurfacing around the mouth to aftercare with or without copper tripeptide products, then measured redness with computer software and blinded evaluators, and graded wrinkles and overall skin quality 12 weeks later; thirteen patients completed the study 1. Read what it was designed to answer: the stated objective was the role of copper tripeptide products in treating laser-resurfaced skin, the primary endpoint was how fast redness resolved, and both arms were healing from a wound rather than being treated for ordinary aging. Everybody improved, because laser resurfacing improves skin. The groups did not differ.
Objective evaluation found no significant improvement in wrinkles or overall skin quality. However, patient satisfaction was significantly higher for those who used GHK-Cu skin care products after CO2 laser skin resurfacing.Miller TR, Wagner JD, Baack BR, Eisbach KJ. Archives of Facial Plastic Surgery, 2006
Thirteen patients is small, a small trial can miss a real effect, and post-laser aftercare is not the same question as treating intact aging skin, so this is one negative result rather than a verdict. The finding to carry is the split inside it: the questionnaire favored the copper peptide (p = 0.04) while the camera and the blinded graders did not. That is the shape of an expectation effect, and it is also the shape of every before-and-after photo posted by somebody who spent $90 on a serum. Our GHK-Cu before and after guide works through what those photos can and cannot show.
The collagen claim starts in a dish of fibroblasts in 1988
Maquart, Pickart and colleagues put GHK-Cu on cultured fibroblasts and measured collagen synthesis. It rose, starting between one and ten picomolar, peaking near one nanomolar, and it was not explained by the cells multiplying 2. That is a clean experiment and it is the origin of every collagen sentence written about copper peptide since. It is also cells in a dish, bathed directly at those very dilute concentrations, with no skin barrier, no blood supply and no ultraviolet light.
The mechanism literature that grew from it is large, most of it consolidated by Pickart and Margolina in 2018, covering gene expression across many cell types 3. The biology in that review is real, and Pickart's affiliation on the paper is Skin Biology, a company selling copper-peptide products, a conflict the field states far less often than it cites the work. The review does describe facial studies in people, including a 71-woman facial cream and a 41-woman eye cream, but those are conference abstracts and pilot studies rather than indexed randomized trials with blinded objective endpoints. That is a claim about study quality, and it is the one the record supports.
Epitalon's human data belongs to a different substance
Epitalon is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) developed by the Khavinson laboratory in St Petersburg, sold on telomerase claims and stacked into anti-aging protocols. The human study people cite for it studied epithalamine, the pineal gland extract that epitalon was modeled on: elderly patients with coronary disease followed for 12 years, reporting lower functional age, better exercise tolerance and lower mortality 4. The abstract does not report how many people were in it, which is a fair thing to know about a study carrying this much weight. Nobody photographed a face. Skin was not an endpoint, and the work comes from one research circle without independent replication.
The elderly-human data comes largely from epithalamine, the pineal extract epitalon was derived from, not the synthetic tetrapeptide itself.
The molecule with the data and the molecule on sale are not the same molecule, and that switch is a pattern rather than an accident; it repeats across this category. The longevity framing, the Khavinson animal work and the telomerase argument live on our anti-aging page. This page stays on faces.
Retinoids hold the trial record; a copper peptide holds a hypothesis
Topical tretinoin has been tested in randomized, double-blind conditions since the 1980s against what trialists call the vehicle, meaning the identical cream with the drug left out. In the University of Michigan study that opened the field, patients applied tretinoin to one forearm and the drug-free cream to the other for 16 weeks, half also received tretinoin on the face and half received the drug-free cream, and 14 of the 15 tretinoin-treated faces improved while none of the drug-free-cream faces did, with matching changes visible in forearm biopsies 6. Thirty-plus years of photoaging trials followed. Irritation was the trade-off then and it still is.
Use both if you want. Do not swap the compound with the trials for the compound with the mechanism. Retinoids drive cell turnover and pigment; a copper peptide is a bet on the structural matrix underneath. Ascorbate, the active form of vitamin C, can strip copper out of the copper-peptide complex, so the two go in different parts of the day, and retinoid and peptide are usually put on alternating evenings rather than layered. That is formulation chemistry rather than a trial finding, and respecting it costs nothing.
Copper peptide on the skin or under it
Injectable GHK-Cu has no trial behind it and no sterile product
Dosing figures for injected GHK-Cu circulate in practitioner protocols and forum posts. They are not reproduced here, because none traces to a published trial and there is no route by which a reader could act on them safely. Facial injection carries infection, granuloma and vascular-injury risk, and vascular injury in the face can end in tissue death or vision loss. No randomized trial of injected GHK-Cu for facial aging has been published, no manufacturer makes an FDA-approved sterile injectable GHK-Cu for facial use, reconstituting a research-grade powder does not make it a sterile pharmaceutical product, and injectable GHK-Cu is still outside any permitted compounding category 8.
Pre-mixed skin blends, and the copper arithmetic nobody runs
Two blends dominate the skin category and both are built around GHK-Cu. GLOW is GHK-Cu, BPC-157 and TB-500, usually 50 mg, 10 mg and 10 mg in a 70 mg vial; KLOW is the same three with 10 mg of KPV added, in an 80 mg vial. BPC-157, TB-500 and KPV are not FDA approved for human use, none of them has facial-aging outcome data, all of them left 503A Category 2 in April 2026 without entering Category 1 8, and BPC-157 and TB-500 sit on the WADA prohibited list, which matters to anyone subject to drug testing. These are supplier products rather than protocols from any study, and no trial has tested the combinations.
Skin and appearance
GLOW
70 mg vialThe skin blend: one collagen peptide and two repair peptides
Skin and appearance
KLOW
80 mg vialGLOW with an anti-inflammatory peptide added
How to judge 12 weeks on your own face
Twelve weeks is the standard window because that is the window the photoaging trials use, including both the Leyden abstract and the Miller trial. It is a trial convention rather than a biological period. Miller's split between the questionnaire and the camera is the reason to build in some discipline before you start, rather than deciding at week 10 whether you look better.
- Photograph at week 0 before changing anythingSame window, same time of day, same angle, no makeup, no filter. One set of photos beats three months of memory.
- Change one thingStarting a peptide serum, a retinoid and an acid in the same week means the result cannot be attributed to any of them.
- Keep sunscreen constantUltraviolet exposure is what the photoaging trials were designed around [[6]]. Varying sun protection mid-experiment ruins the comparison as well as the skin.
- Re-photograph at week 6 and week 12Compare week 12 against week 0 side by side, not against your memory of your face. Judge before you read the mirror.
- Expect the answer to be no changeThat is the answer the blinded evaluators gave in the one independent facial trial [[1]], and a null result on your own face is information you can use.
On cost and storage: a cosmetic copper peptide serum at a usable concentration typically runs $30 to $130, while over-the-counter adapalene 0.1 percent, the compound with the trial record, sits nearer $15 to $20 for a tube that lasts months. Copper peptide solutions are kept away from heat and sunlight. If you are weighing this alongside other age-related goals, peptides after 50 covers the wider picture.
What your genes say about skin aging, and what they cannot say
This section is mechanism plus hypothesis, and saying so is the honest version. Four variants have real literature on collagen, elastin, matrix turnover and oxidative stress biology. None of them has been tested against a peptide's effect on skin, by anyone.
- **COL1A1 rs1800012** sits in an Sp1 transcription-factor binding site and shifts type I collagen chain ratios. The evidence base is bone mineral density research; relevance to skin collagen is assumed rather than shown.
- **ELN rs2071307** is an elastin gene variant with literature on tissue elasticity. Elastin barely regenerates in adult skin, which is part of why lost firmness is harder to reverse than lost hydration.
- **MMP1 rs1799750** is the -1607 1G/2G promoter insertion/deletion, or indel, linked to higher transcription of the enzyme that degrades collagen. Consumer genotyping chips generally cannot read insertions and deletions, so an uploaded 23andMe or AncestryDNA file usually has no call for it.
- **SOD2 rs4880 (Ala16Val)** shapes how efficiently mitochondria handle oxidative stress, which is genuine photoaging biology; the peptides argued to act on that machinery directly are covered on peptides for mitochondrial health. No peptide-response data exists for it.
If your file shows the low-COL1A1, high-MMP1 pattern, the mechanistic argument for a collagen-supporting ingredient is at its strongest, and it remains untested: no trial has stratified any skin peptide's outcome by genotype. A genetic report can rank that hypothesis against your own variants and tell you which markers your file could not read. It cannot predict your response, and anyone selling it as prediction is selling something else. What a consumer report does and does not call is worked through in our SelfDecode peptide report review, and the DNA decision framework sets out where the line sits.
What the evidence supports
- Sunscreen daily and a retinoid at night are the two steps with regulator-reviewed status and decades of photoaging trials 6. Everything on this page is layered on top of them, never instead. Which retinoid, at what strength, and whether one suits your skin at all is a decision for a dermatologist; prescription retinoids are contraindicated in pregnancy.
- If you want a peptide with human outcome data, pal-KTTKS at 3 ppm has the split-face trial 5, on the label as palmitoyl pentapeptide-4. GHK-Cu has the deeper mechanism literature and the thinner human record.
- Treat a copper peptide serum as a 12-week experiment with photographs, and treat injecting it as an unstudied procedure with real risks.
Further reading, by the question you arrived with. Copper peptide for hair and scalp runs on a different and weaker citation chain, graded on peptides for hair loss. Persistent redness and barrier problems sit on peptides for inflammation. Compound-level detail is on GHK-Cu, epitalon and BPC-157, the last of which has no skin-aging data but a much larger literature on tissue repair, graded on peptides for injury recovery.
article · U.S. Food and Drug AdministrationFDA: bulk drug substances for compounding that may present significant safety risksThe Category 2 page, current as of 22 April 2026. Injectable GHK-Cu, epitalon, BPC-157, TB-500 and KPV were placed in Category 2 in September 2023 and now appear in the separate table of substances whose nominations were withdrawn. FDA's stated safety concerns about each are still published there, and none of them was added to Category 1, so compounding pharmacies still may not prepare them.fda.govDisclosure: vendor links on this site, including those on our comparison page, are affiliate links, and we earn a commission if you buy through them. That does not change the grading above, which is why this page's evidence table puts a retinoid ahead of every peptide on it. Some listings there are telehealth providers prescribing compounded GHK-Cu. Compounded injectable GHK-Cu is not currently authorized under section 503A, no randomized trial supports injecting it for facial aging, and nothing on this page is a recommendation to obtain it.
Your collagen, elastin and oxidative-stress variants are readable from the raw DNA data you already have. Upload it and get all 39 peptides ranked by how well each one's mechanism matches your genotype, with the markers your file could not read named plainly. That is a ranking of plausibility, not a prediction of how you will respond: no trial has stratified any skin peptide by genotype. It is not medical advice and it does not recommend a compound.
Get your DNA report- Mechanism-rich, outcome-poor
GHK-Cu has the longest laboratory record of any cosmetic peptide and the weakest human record. Forty years of cell-culture and gene-expression work sit behind it, descending from fibroblasts bathed in a controlled concentration in 1988 with no skin barrier, no blood supply and no ultraviolet light between the peptide and the cell. Not one blinded facial outcome measure has come out the other side.
Frequently asked questions
What do peptides do for skin?
In principle they act as signals: a short chain of amino acids that resembles a fragment of broken collagen tells fibroblasts, the cells that build skin's scaffolding, to build more. GHK-Cu adds a carried copper ion, and copper is required by lysyl oxidase, the enzyme that cross-links collagen and elastin. In cultured cells that signaling is measurable and reproducible. On faces, the one cosmetic peptide with a clean split-face randomized trial behind it is pal-KTTKS at 3 parts per million, which reduced wrinkles and fine lines over 12 weeks in 93 Caucasian women aged 35 to 55, in a single trial run by the manufacturer's own scientists.
What are the best peptides for skin?
Graded by human evidence rather than by marketing: pal-KTTKS (Matrixyl) first, because it has a 12-week double-blind split-face trial with image analysis and expert grading, though it is one manufacturer-run trial in Caucasian women and nobody has replicated it. Topical GHK-Cu second, on a large mechanism literature plus one independent facial trial that was negative on the objective measures. Injectable GHK-Cu, epitalon and BPC-157 have no facial-aging outcome data in people, none of the three is FDA approved, and all three left Category 2 of the FDA's interim 503A list in April 2026 without being added to Category 1, so licensed compounding pharmacies still may not legally prepare them. None of them outranks a retinoid and daily sunscreen, which is where the trial record is.
Do collagen peptides you swallow help skin?
Oral collagen peptides are a different product from the peptides graded on this page: hydrolyzed protein you swallow, not a signal applied to skin. The randomized trials that exist mostly measure probe-read hydration and elasticity over 8 to 12 weeks, and the ones we located list collagen manufacturers as funders. We have not found a head-to-head trial against a retinoid. Treat a collagen powder as protein with a possible hydration effect, and not as a substitute for sunscreen or a retinoid.
Can I use a copper peptide serum with vitamin C or a retinoid?
Both pairings are usually applied separately rather than layered. High-dose vitamin C (ascorbate) can strip copper out of the copper-peptide complex, which is formulation chemistry rather than a trial finding, so one goes in the morning and the other in the evening. Retinoid and copper peptide are commonly alternated across evenings; retinoids drive cell turnover and pigment while the peptide is a bet on the matrix underneath. The rule to keep is that the retinoid is the one with the trials, so it should not be the one you drop. Which retinoid and how often is a question for a dermatologist.
Sources8
- Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg 2006;8(4):252-9 (13 patients completed, randomized post-laser aftercare; primary endpoint erythema resolution; no significant difference on computer analysis or blinded evaluators)
- Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett 1988;238(2):343-6 (cultured fibroblasts, in vitro; release of GHK from collagen at a wound is raised as a suggestion, not shown)
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018;19(7):1987 (mechanism review; the human facial studies it describes are conference abstracts and pilot studies, not indexed randomized trials; author affiliation is a company selling copper-peptide products)
- Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bull Exp Biol Med 2006;142(3):356-9 (12-year study of the extract, not the synthetic tetrapeptide; no subject count reported in the abstract; no skin endpoints)
- Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci 2005;27(3):155-60 (n=93 Caucasian women aged 35-55, 12-week double-blind split-face randomized study, 3 ppm pal-KTTKS; manufacturer-run, not independently replicated)
- Weiss JS, Ellis CN, Headington JT, Tincoff T, Hamilton TA, Voorhees JJ. Topical tretinoin improves photoaged skin. A double-blind vehicle-controlled study. JAMA 1988;259(4):527-32 (16 weeks; 14 of 15 tretinoin-treated faces improved, none of the vehicle-treated faces)
- Shuster S, Black MM, McVitie E. The influence of age and sex on skin thickness, skin collagen and density. Br J Dermatol 1975;93(6):639-43 (descriptive study; skin collagen declines roughly 1% per year after age 25; not an intervention trial)
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 of the 503A/503B interim policies), page current as of 22 April 2026 (injectable GHK-Cu, epitalon, BPC-157, TB-500 and KPV listed under substances nominated but withdrawn, with FDA's safety rationale retained; none added to Category 1)
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary. Some outbound links are affiliate links, at no extra cost to you.
This page is educational and is not medical advice. Peptides are not intended to diagnose, treat, cure, or prevent any disease, and most are not FDA-approved. Talk to a qualified healthcare provider before starting anything. Availability and legal status of peptides vary by jurisdiction.
← All condition guides